Zulcaif Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zulcaif Ahmad has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
- Asif Mahmood
Department of Pharmacy, University of Chakwal, Chakwal 48800, Pakistan
13 shared publications - Muhammad Imran Khan
Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University, Lahore, Pakistan
9 shared publications - Rai Muhammad Sarfraz
Department of Pharmaceutics, College of Pharmacy, University of Sargodha, Sargodha, Pakistan
7 shared publications - Muhammad Farhan Sohail
Department of Pharmacy, University of South Asia, Lahore, Pakistan
5 shared publications - Muhammad Furqan Akhtar
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore Campus, Lahore, Pakistan.
5 shared publications Rai Muhammad Sarfraz
5 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (9) , 557
Formulation and In vitro Characterization of Rosuvastatin Calcium Loaded Chitosan Nanoparticles for Sustained Drug Release
- 24 August 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (9) , 557
Formulation and In vitro Characterization of Rosuvastatin Calcium Loaded Chitosan Nanoparticles for Sustained Drug Release
- 5 March 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (3) , 227
Preparation and Evaluation of Silver Nanoparticles Loaded Film Forming Gel; Co-Delivering Linezolid and Rosuvastatin for Diabetic Foot Wound
- 5 March 2026
- Published by Springer Nature in BioNanoScience
- Vol. 16 (3) , 227
Preparation and Evaluation of Silver Nanoparticles Loaded Film Forming Gel; Co-Delivering Linezolid and Rosuvastatin for Diabetic Foot Wound
- 15 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 4083-4097
Curative potential of resveratrol and pterostilbene against epoxy resin–induced reproductive toxicity in female rats
Epoxy resin is the precursor of bisphenol A and is an important component in a wide range of daily used products. It produces toxic effects by oxidative stress, inflammation and endocrine disruption. Its exposure to humans occur through inhalation, dermal contact and ingestion. Several studies link the epoxy resin components to reproductive toxicity including impaired ovarian function and hormonal imbalance in males and females. The study was aimed to assess the reproductive toxicity in female rats due to epoxy resin exposure and demonstrate the curative potential of resveratrol and pterostilbene against epoxy resin–induced reproductive toxicity. The study included eight groups of rats (n = 6). One was the control group receiving only vehicle, while the other one was the epoxy resin–treated group in which the female rats were given orally epoxy resin at 15 mg/kg/day for 4 weeks. Other six groups were administered resveratrol and pterostilbene orally at different doses (50, 25 and 12.5 mg/kg/day) for 4 weeks. Dose selection was performed according to the previously published data. After the study duration, female rats were ovariectomized and assessed for body weight changes, oxidative stress and histopathological changes. ELISA analysis was performed for inflammatory markers in ovaries while caspase-3 gene was evaluated in ovaries by PCR. Statistical comparison was performed by one-way ANOVA followed by Tukey’s post hoc test. The subsequent treatment with resveratrol and pterostilbene depicted marked improvements in LH, FSH, estrogen, progesterone and testosterone levels. The female rats exposed to epoxy resin showed a high content of the caspase-3 gene responsible for apoptosis. Moreover, the oxidative stress markers such as SOD, CAT and GSH were increased while MDA decreased in the ovary of rats treated with resveratrol and pterostilbene, whereas anti-inflammatory markers such as TNF-α and NF-κB were increased significantly with the epoxy resin exposure but treatment drugs employed reduction in their levels significantly. It was concluded that epoxy resin produced marked damage to the ovary and this toxicity can be reduced with resveratrol and pterostilbene treatments.
- 15 October 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (3) , 4083-4097
Curative potential of resveratrol and pterostilbene against epoxy resin–induced reproductive toxicity in female rats
Epoxy resin is the precursor of bisphenol A and is an important component in a wide range of daily used products. It produces toxic effects by oxidative stress, inflammation and endocrine disruption. Its exposure to humans occur through inhalation, dermal contact and ingestion. Several studies link the epoxy resin components to reproductive toxicity including impaired ovarian function and hormonal imbalance in males and females. The study was aimed to assess the reproductive toxicity in female rats due to epoxy resin exposure and demonstrate the curative potential of resveratrol and pterostilbene against epoxy resin–induced reproductive toxicity. The study included eight groups of rats (n = 6). One was the control group receiving only vehicle, while the other one was the epoxy resin–treated group in which the female rats were given orally epoxy resin at 15 mg/kg/day for 4 weeks. Other six groups were administered resveratrol and pterostilbene orally at different doses (50, 25 and 12.5 mg/kg/day) for 4 weeks. Dose selection was performed according to the previously published data. After the study duration, female rats were ovariectomized and assessed for body weight changes, oxidative stress and histopathological changes. ELISA analysis was performed for inflammatory markers in ovaries while caspase-3 gene was evaluated in ovaries by PCR. Statistical comparison was performed by one-way ANOVA followed by Tukey’s post hoc test. The subsequent treatment with resveratrol and pterostilbene depicted marked improvements in LH, FSH, estrogen, progesterone and testosterone levels. The female rats exposed to epoxy resin showed a high content of the caspase-3 gene responsible for apoptosis. Moreover, the oxidative stress markers such as SOD, CAT and GSH were increased while MDA decreased in the ovary of rats treated with resveratrol and pterostilbene, whereas anti-inflammatory markers such as TNF-α and NF-κB were increased significantly with the epoxy resin exposure but treatment drugs employed reduction in their levels significantly. It was concluded that epoxy resin produced marked damage to the ovary and this toxicity can be reduced with resveratrol and pterostilbene treatments.
- 9 October 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (11) , 6839-6860
Fabrication of bergapten loaded microneedle patch and assessment of its anti-arthritic potential against complete Freund’s adjuvant induced arthritis in Wistar rat
This research study was designed to fabricate bergapten-loaded biodegradable microneedle patches (BP-MNPs) and assess its anti-arthritic potential. The BP-MNPs were synthesized by solvent casting technique using polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) as polymers, followed by their characterization. The in vitro release study and stability study were also conducted. X-ray diffraction analysis of BP-MNPs showed a broad range of crystallographic planes, while SEM analysis showed unfractured, sharp tips with a length of 500 µm and a base of 200 µm. The anti-arthritic potential of BP-MNPs was investigated by inserting 0.15 ml of Complete Freund’s adjuvant (CFA) into the tail vein of Wistar rats on day 1 to develop a CFA-induced arthritic model. Treatment begins on the 8th day and continues till the 28th day. Methotrexate was administered orally (1 mg/kg) as the standard treatment. The BP-MNPs significantly (p < 0.001–0.0001) decreased paw swelling, arthritic scoring, pain, and restored body weight compared to orally administered bergapten and the standard treatment. The blood parameters were also restored by BP-MNPs, along with the restoration of oxidative stress biomarkers in liver homogenate and neurotransmitter levels in sciatic nerve homogenate. Treatment with BP-MNPs notably (p < 0.0001) reduced the mRNA expression of IL-6, COX-2, TNF-α, and NF-κB, while upregulating IL-4 in contrast to disease control and standard treatment groups. Treatment with BP-MNPs also improved the histology of the ankle joint and sciatic nerve. It can be concluded from the current study data that BP-MNPs at a dose of 10 mg/kg exhibited significant anti-arthritic and anti-nociceptive responses in arthritic rats in contrast to bergapten and the standard drug. Graphical abstract
- 9 October 2025
- Published by Springer Nature in Inflammopharmacology
- Vol. 33 (11) , 6839-6860
Fabrication of bergapten loaded microneedle patch and assessment of its anti-arthritic potential against complete Freund’s adjuvant induced arthritis in Wistar rat
This research study was designed to fabricate bergapten-loaded biodegradable microneedle patches (BP-MNPs) and assess its anti-arthritic potential. The BP-MNPs were synthesized by solvent casting technique using polyvinyl pyrrolidone (PVP) and polyvinyl alcohol (PVA) as polymers, followed by their characterization. The in vitro release study and stability study were also conducted. X-ray diffraction analysis of BP-MNPs showed a broad range of crystallographic planes, while SEM analysis showed unfractured, sharp tips with a length of 500 µm and a base of 200 µm. The anti-arthritic potential of BP-MNPs was investigated by inserting 0.15 ml of Complete Freund’s adjuvant (CFA) into the tail vein of Wistar rats on day 1 to develop a CFA-induced arthritic model. Treatment begins on the 8th day and continues till the 28th day. Methotrexate was administered orally (1 mg/kg) as the standard treatment. The BP-MNPs significantly (p < 0.001–0.0001) decreased paw swelling, arthritic scoring, pain, and restored body weight compared to orally administered bergapten and the standard treatment. The blood parameters were also restored by BP-MNPs, along with the restoration of oxidative stress biomarkers in liver homogenate and neurotransmitter levels in sciatic nerve homogenate. Treatment with BP-MNPs notably (p < 0.0001) reduced the mRNA expression of IL-6, COX-2, TNF-α, and NF-κB, while upregulating IL-4 in contrast to disease control and standard treatment groups. Treatment with BP-MNPs also improved the histology of the ankle joint and sciatic nerve. It can be concluded from the current study data that BP-MNPs at a dose of 10 mg/kg exhibited significant anti-arthritic and anti-nociceptive responses in arthritic rats in contrast to bergapten and the standard drug. Graphical abstract
- 14 August 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (6) , 247
A tetrahydropyrimidine derivative demonstrates neuroprotection against ketamine-induced schizophrenia through moderating oxidative and inflammatory markers
Schizophrenia impacts individuals' cognition, perceptions, behavior and memory and influences almost 1-1.5% of the global population. It is a psychotic disorder possibly caused by high levels of immunostimulants as well as oxygen-derived free radicals in the blood and CSF. As observed in the studies that pyrimidine derivatives (THP) have promising potential to act as anti-inflammatory agents, therefore these may be helpful in treating schizophrenia. So, this study evaluated the preventive potential of THP in treating schizophrenia induced by ketamine. The mice were segregated in six groups, normal control received 0.5% CMC 1 ml/kg I.P.), disease control and other groups received ketamine 10 mg/kg I.P. Clozapine (1 mg/kg I.P.) served as standard drug. Other groups received THP (10 mg/kg/day I.P.), THP (15 mg/kg/day I.P.) and THP (20 mg/kg/day I.P.). Study was designed as a preventive trial spanning 21-days with initial 14 days treatment, followed by a subsequent 7-day ketamine administration. The study demonstrated that the improvement of positive, negative and cognitive symptoms in THP-treated animals by significantly reducing stereotypic behaviors and inactivity in forced swim and tail suspension tests, and accelerating center time in Open field test and number of entries and alteration in Y-maze test. Oxidative stress in schizophrenic mice was also managed by marked elevation in SOD and CAT levels, and the parameters like GSH, MDA and nitrite contents were significantly reduced. In addition, inflammatory markers such as TNF-α, IL-6, NF-κB and MAP-K were significantly reduced. Furthermore, gene expression showed significant incline in BDNF levels, after THP administration in schizophrenic mice. Overall, the study disclosed THP as an effective compound in mitigating the symptoms of schizophrenia, however further study is needed to evaluate its toxicity profile.
- 14 August 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (6) , 247
A tetrahydropyrimidine derivative demonstrates neuroprotection against ketamine-induced schizophrenia through moderating oxidative and inflammatory markers
Schizophrenia impacts individuals' cognition, perceptions, behavior and memory and influences almost 1-1.5% of the global population. It is a psychotic disorder possibly caused by high levels of immunostimulants as well as oxygen-derived free radicals in the blood and CSF. As observed in the studies that pyrimidine derivatives (THP) have promising potential to act as anti-inflammatory agents, therefore these may be helpful in treating schizophrenia. So, this study evaluated the preventive potential of THP in treating schizophrenia induced by ketamine. The mice were segregated in six groups, normal control received 0.5% CMC 1 ml/kg I.P.), disease control and other groups received ketamine 10 mg/kg I.P. Clozapine (1 mg/kg I.P.) served as standard drug. Other groups received THP (10 mg/kg/day I.P.), THP (15 mg/kg/day I.P.) and THP (20 mg/kg/day I.P.). Study was designed as a preventive trial spanning 21-days with initial 14 days treatment, followed by a subsequent 7-day ketamine administration. The study demonstrated that the improvement of positive, negative and cognitive symptoms in THP-treated animals by significantly reducing stereotypic behaviors and inactivity in forced swim and tail suspension tests, and accelerating center time in Open field test and number of entries and alteration in Y-maze test. Oxidative stress in schizophrenic mice was also managed by marked elevation in SOD and CAT levels, and the parameters like GSH, MDA and nitrite contents were significantly reduced. In addition, inflammatory markers such as TNF-α, IL-6, NF-κB and MAP-K were significantly reduced. Furthermore, gene expression showed significant incline in BDNF levels, after THP administration in schizophrenic mice. Overall, the study disclosed THP as an effective compound in mitigating the symptoms of schizophrenia, however further study is needed to evaluate its toxicity profile.
- 11 June 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (3) , 1-12
Transdermal Co-Delivery of Sumatriptan Succinate and Naproxen Sodium via Dissolving Microneedle Patch
- 11 June 2025
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 20 (3) , 1-12
Transdermal Co-Delivery of Sumatriptan Succinate and Naproxen Sodium via Dissolving Microneedle Patch
- 3 June 2025
- Published by Springer Nature in Colloid and Polymer Science
- Vol. 303 (8) , 1695-1704
Development and characterization of chlorquinaldol-loaded nanogels: a promising topical delivery system with sustained release and enhanced antimicrobial efficacy
- 3 June 2025
- Published by Springer Nature in Colloid and Polymer Science
- Vol. 303 (8) , 1695-1704
Development and characterization of chlorquinaldol-loaded nanogels: a promising topical delivery system with sustained release and enhanced antimicrobial efficacy
- 8 May 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (11) , 15561-15572
Nanogel-based delivery of dequalinium chloride: A novel approach for antimicrobial and controlled drug release
Dequalinium chloride (DQC) is a potent antimicrobial agent; however, its therapeutic application is limited due to poor solubility, rapid degradation, and short half-life. In this study, we developed a nanogel-based delivery system to provide stability, bioavailability, and controlled release of DQC, subsequently improving antimicrobial impact. Carbopol 940 and PEG 6000 were used for the synthesis of the nanogel, which was characterized for physicochemical properties, drug entrapment, and release kinetics. Differential Scanning Calorimetry (DSC), and X-ray Diffraction (XRD) confirmed the successful encapsulation and amorphous nature, whereas Thermogravimetric Analysis (TGA) validated improved thermal stability. The nanogel showed a high entrapment efficiency of 90%, and the drug was released sustained according to a non-Fickian diffusion mechanism with 86.23% cumulative release in 24 h. As per antimicrobial activity, it was observed that the developed formulation showed better inhibition against Escherichia coli and Staphylococcus aureus than free drug solutions. Thus, the findings indicate that the developed nanogel formulation can be considered a worthy advanced antimicrobial delivery system with controlled drug release. Graphical Abstract
- 8 May 2025
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (11) , 15561-15572
Nanogel-based delivery of dequalinium chloride: A novel approach for antimicrobial and controlled drug release
Dequalinium chloride (DQC) is a potent antimicrobial agent; however, its therapeutic application is limited due to poor solubility, rapid degradation, and short half-life. In this study, we developed a nanogel-based delivery system to provide stability, bioavailability, and controlled release of DQC, subsequently improving antimicrobial impact. Carbopol 940 and PEG 6000 were used for the synthesis of the nanogel, which was characterized for physicochemical properties, drug entrapment, and release kinetics. Differential Scanning Calorimetry (DSC), and X-ray Diffraction (XRD) confirmed the successful encapsulation and amorphous nature, whereas Thermogravimetric Analysis (TGA) validated improved thermal stability. The nanogel showed a high entrapment efficiency of 90%, and the drug was released sustained according to a non-Fickian diffusion mechanism with 86.23% cumulative release in 24 h. As per antimicrobial activity, it was observed that the developed formulation showed better inhibition against Escherichia coli and Staphylococcus aureus than free drug solutions. Thus, the findings indicate that the developed nanogel formulation can be considered a worthy advanced antimicrobial delivery system with controlled drug release. Graphical Abstract
- Open Access
- 8 April 2025
- Published by Akademiai Kiado Zrt. in Acta Chromatographica
- Vol. 37 (2) , 176-182
Method development and validation of Metformin HCL and Dapagliflozin by using RP-HPLC
The prevalence of diabetes is increasing day by day as per a report by the year 2045, 1 out of every 8th individuals may suffer from diabetes. This research article focuses on developing and validating Metformin and Dapagliflozin in combination by using high-pressure liquid Chromatography (RP-HPLC). The validation of the method was followed as per the guidelines provided by the International Conference on Harmonization (ICH) and United States Pharmacopeia (USP). Separation of both drugs takes place in less than 4 min. This separation takes place using Phosphate buffer (pH 6.8) and acetonitrile in a 45:55 (v/v) ratio at a 1.0 mL min−1 flow rate. Furthermore, studies on both drugs were conducted by using the bulk and pharmaceutical dosage forms (Tablets). The developed method was accurate as drug recoveries in both cases of Metformin, and Dapagliflozin ranged between (100.8, 99.6, 98.8%) to (100.8, 99.3, and 101.5%) respectively having a concentration range of solutions between 70, 100 and 130 μg mL−1 dilution. The recommended method for simultaneous quantification of Metformin and Dapagliflozin was established and validated and no excipient interactions were found.
- 8 April 2025
- Published by Akademiai Kiado Zrt. in Acta Chromatographica
- Vol. 37 (2) , 176-182
Open AccessMethod development and validation of Metformin HCL and Dapagliflozin by using RP-HPLC
The prevalence of diabetes is increasing day by day as per a report by the year 2045, 1 out of every 8th individuals may suffer from diabetes. This research article focuses on developing and validating Metformin and Dapagliflozin in combination by using high-pressure liquid Chromatography (RP-HPLC). The validation of the method was followed as per the guidelines provided by the International Conference on Harmonization (ICH) and United States Pharmacopeia (USP). Separation of both drugs takes place in less than 4 min. This separation takes place using Phosphate buffer (pH 6.8) and acetonitrile in a 45:55 (v/v) ratio at a 1.0 mL min−1 flow rate. Furthermore, studies on both drugs were conducted by using the bulk and pharmaceutical dosage forms (Tablets). The developed method was accurate as drug recoveries in both cases of Metformin, and Dapagliflozin ranged between (100.8, 99.6, 98.8%) to (100.8, 99.3, and 101.5%) respectively having a concentration range of solutions between 70, 100 and 130 μg mL−1 dilution. The recommended method for simultaneous quantification of Metformin and Dapagliflozin was established and validated and no excipient interactions were found.
- 10 March 2025
- Published by Institutul de Chimie Macromoleculara Petru Poni in Cellulose Chemistry and Technology
- Vol. 59 (3-4) , 387-398
POLYMERIC NANOPARTICLES ENHANCE THE AQUEOUS SOLUBILITY AND THERAPEUTIC DELIVERY OF DOCETAXEL
This study aimed to develop docetaxel (DTX)-loaded polymeric nanoparticles based on chitosan and its combinations with β-cyclodextrin or Poloxamer 188 to improve the dissolution profile of DTX. Three nanoparticle groups were formulated using the ionic gelation method: chitosan-based (F1CS, F2CS, F3CS), chitosan/β-cyclodextrin-based (F1βCS, F2βCS, F3βCS), and chitosan/Poloxamer 188-based (F1PCS, F2PCS, F3PCS). The compatibility between DTX and the formulation components was confirmed using FTIR. Nanoparticle morphology was examined via SEM, and the physical state of the drug was analyzed using DSC and TGA. In vitro drug release was determined using the dialysis bag method. Entrapment efficiency ranged from 55.90 to 82.07% for chitosan-based nanoparticles, 80.80% to 95.13% for β-cyclodextrin-chitosan nanoparticles, and 86.36% to 98.90% for Poloxamer 188-chitosan nanoparticles. SEM analysis showed spherical morphology, and DSC confirmed the amorphous state of DTX. The optimized formulation (F3PCS) demonstrated a sustained release profile. The findings suggest that chitosan-based nanoparticles, combined with β-cyclodextrin and Poloxamer 188, provide a promising approach for enhancing the solubility and bioavailability of DTX.
- 10 March 2025
- Published by Institutul de Chimie Macromoleculara Petru Poni in Cellulose Chemistry and Technology
- Vol. 59 (3-4) , 387-398
POLYMERIC NANOPARTICLES ENHANCE THE AQUEOUS SOLUBILITY AND THERAPEUTIC DELIVERY OF DOCETAXEL
This study aimed to develop docetaxel (DTX)-loaded polymeric nanoparticles based on chitosan and its combinations with β-cyclodextrin or Poloxamer 188 to improve the dissolution profile of DTX. Three nanoparticle groups were formulated using the ionic gelation method: chitosan-based (F1CS, F2CS, F3CS), chitosan/β-cyclodextrin-based (F1βCS, F2βCS, F3βCS), and chitosan/Poloxamer 188-based (F1PCS, F2PCS, F3PCS). The compatibility between DTX and the formulation components was confirmed using FTIR. Nanoparticle morphology was examined via SEM, and the physical state of the drug was analyzed using DSC and TGA. In vitro drug release was determined using the dialysis bag method. Entrapment efficiency ranged from 55.90 to 82.07% for chitosan-based nanoparticles, 80.80% to 95.13% for β-cyclodextrin-chitosan nanoparticles, and 86.36% to 98.90% for Poloxamer 188-chitosan nanoparticles. SEM analysis showed spherical morphology, and DSC confirmed the amorphous state of DTX. The optimized formulation (F3PCS) demonstrated a sustained release profile. The findings suggest that chitosan-based nanoparticles, combined with β-cyclodextrin and Poloxamer 188, provide a promising approach for enhancing the solubility and bioavailability of DTX.